CPT code 0265T covers autologous bone marrow harvest, preservation, and subsequent intramuscular injection intended to treat conditions such as end-stage peripheral artery disease. The code captures both the procurement and storage of autologous bone marrow for later therapeutic implantation, representing an advanced biologic and regenerative approach to limb ischemia and related vascular conditions. Nationally, this code is relevant as regenerative therapies expand and payers evaluate coverage policies for cell-based interventions.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical intent of the service, typical settings where the procedure is delivered, and the payer landscape relevant to coverage decisions. The publication summarizes available benchmarks where present, highlights common billing and documentation considerations tied to this service line, and flags policy and coding updates that affect how payers classify and reimburse autologous bone marrow therapies.

This summary equips clinical billers, revenue leaders, and policy analysts with the contextual information needed to identify where CPT code 0265T fits in regenerative vascular care, what payers are commonly involved, and which operational and policy topics to pursue for deeper review. Data not available in the input is noted where applicable in subsequent sections.